欧文原著

1. Bono Y, Kyo S, Kiyono T, Mizumoto Y, Nakamura M, Maida Y, Takakura M, Fujiwara H.
Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives.
Fertil.Steril. in press.(IF:4.174)

2. Zhang X, Kyo S
#, Nakamura M, Mizumoto Y, Maida Y, Bono Y, Takakura M, FujiwaraH.
Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Cancer Lett. 345: 106-114, 2014.(IF:4.258)

3. Mita S, Shimizu Y, Sato A, Notsu T, Imada K and Kyo S
#.
Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β.
Fertil.Steril. 101:595-601, 2014.(IF:4.174)

4.Nakamura M, Zhang X, Mizumoto Y, Maida Y, Bono Y, Takakura M and Kyo S
#.
Molecular characterization of CD133+ cancer stem-lie cells in endometrial cancer.
Int.J.Oncol. 44: 669-677, 2014.(IF:2.657)

5. Itoh F, Komohara Y, Takaishi K, Honda R, Tashiro H, Kyo S, Katabuchi H, Takeya M. Possible involvement of signal transducer and activator of transcription-3 in cell-cell interactions of peritoneal macrophages and endometrial stromal cells in human endometriosis.
Fertil. Steril., 99:1705-1713, 2013.(IF:4.174)

6.Maida Y, Kyo S, Lassmann T, Hayashizaki Y, Masutomi K.
Off-target effect of endogenous siRNA derived from RMRP in human cells.
Int. J. Mol. Sci., 14: 9305-9318, 2013. (IF:2.244)

7. Nakamura M, Takakura M, Fujii R, Maida Y, Bono Y, Mizumoto Y, Zhang X, Kiyono T, Kyo S
#.
The PRB-dependent FOXO1/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth.
Cancer Lett., 336: 68-75, 2013.(IF:4.258)

8. Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, Fujimoto M, Kimura T, Naka T.
Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.
Int. J. Cancer, 132: 472-484, 2013. (IF:6.198)

9. Zhou K, Koike C, Yoshida T, Okabe M, Fathy M, Kyo S, Kiyono T, Saito S, Nikaido T. Establishment and characterization of immortalized human amniotic epithelial cells.
Cell Reprogram., 15: 55-67, 2013. (IF:2.744)

10. Teng Z, Yoshida T, Okabe M, Toda A, Higuchi O, Nogami M, Yoneda N, Zhou K,
Kyo S, Kiyono T, Nikaido T.
Establishment of immortalized human amniotic mesenchymal stem cells.
Cell Transplant., 22: 267-278, 2013. (IF:4.422)

11. Takakura M, Kyo S, Nakamura M, Maida Y, Mizumoto Y, Bono Y, Zhang X, Hashimoto Y, Urata Y, Fujiwara T, Inoue M.
Circulating tumor cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers.
Br. J. Cancer, 107: 448-454, 2012. (IF:5.082)

12. Bono Y, Kyo S
#, Takakura M, Maida Y, Mizumoto Y, Nakamura M, Nomura K, Kiyono T, Inoue M.
Creation of immortalized epithelial cells from ovarian endometrioma.
Br. J. Cancer, 106: 1205-1213, 2012. (IF:5.082)

13. Shinohara A, Kutsukake M, Takahashi M, Kyo S, Tachikawa E, Tamura K. Protease-activated receptor-stimulated interleukin-6 expression in endometriosis-like lesions in an experimental mouse model of endometriosis.
J. Pharmacol. Sci., 119: 40-51, 2012. (IF:2.150)

14. Mita S, Shimizu Y, Notsu T, Imada K, Kyo S.
Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells.
Fertil. Steril., 96: 1485-1489, 2011. (IF:4.174)

15. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S.
Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system.
Steroids, 76: 60-67, 2011. (IF:2.803)

16. Ohno S, Takano F, Ohta Y, Kyo S, Myojo S, Dohi S, Sugiyama H, Ohta T, Inoue M. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Anticancer Res., 31: 2447-2452, 2011. (IF:1.713)

17. Dohi S, Ohno S, Ohno Y, Takakura M, Kyo S, Soma G, Sugiyama H, Inoue M.
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Anticancer Res., 31: 2441-2445, 2011. (IF:1.713)

18. Ohno S, Sumiyoshi Y, Hashine K, Shirato A, Kyo S, Inoue M.
Phase I clinical study of the dietary supplement, Agaricus blazei murill, in cancer patients in remission.
Evid. Based Complement. Alternat. Med., 2011:192381, 2011.(IF:1.722)

19. Mizumoto Y, Kyo S
#, Kiyono T, Takakura M, Nakamura M, Maida Y, Mori N, Bono Y, Sakurai H, Inoue M.
Activation of NF-κB is a novel target of KRAS-induced endometrial carcinogenesis.
Clin. Cancer Res. 17: 1341-1350, 2011. (IF:7.837)

20. Kyo S
#, Sakaguchi J, Kiyono T, Shimizu Y, Maida Y, Mizumoto Y, Mori N, Nakamura M, Takakura M, Miyake M, Sakamoto M, Inoue M.
Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth.
Clin. Cancer Res., 17: 525-537, 2011. (IF:7.837)

21. Wong CW, Hou PS, Tseng SF, Chien CL, Wu KJ, Chen HF, Ho HN, Kyo S, Teng SC. Krüppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells.
Stem Cells, 28: 1510-1517, 2010. (IF:7.701)

22. Mori N, Kyo S
#, Nakamura M, Hashimoto M, Maida Y, Mizumoto Y, Takakura M, Ohno S, Kiyono T, Inoue M.
Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer.
Br. J. Cancer, 103: 889-898, 2010. (IF:5.082)

23. Nakamura M, Kyo S
#, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M.
Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.
Hum. Pathol., 41: 1516-1529, 2010. (IF:2.843)

24. Dohi S, Ohno S, Ohno Y, Kyo S, Soma G, Sugiyama H, Inoue M.
WT1 expression correlates with angiogenesis in endometrial cancer tissue.
Anticancer Res., 30: 3187-3192, 2010. (IF:1.713)

25. Kojima T, Watanabe Y, Hashimoto Y, Kuroda S, Yamasaki Y, Yano S, Ouchi M, Tazawa H, Uno F, Kagawa S, Kyo S, Mizuguchi H, Urata Y, Tanaka N, Fujiwara T.
In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.
Ann. Surg., 251: 1079-1086, 2010. (IF:6.329)

26. Watanabe Y, Kojima T, Kagawa S, Uno F, Hashimoto Y, Kyo S, Mizuguchi H, Tanaka N, Kawamura H, Ichimaru D, Urata Y, Fujiwara T.
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
Oncogene, 29: 1145-1154, 2010. (IF:7.357)

27. Takakura M, Nakamura M, Kyo S
#, Hashimoto M, Mori N, Ikoma T, Mizumoto Y, Fujiwara T, Urata Y, Inoue M.
Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Cancer Gene Ther., 17: 11-19, 2010. (IF:2.945)

28. Shimizu Y, Takeuchi T, Mita S, Notsu T, Mizuguchi K, Kyo S.
Krüppel-like factor 4 mediates anti-proliferative effects of progesterone with G
0/G1 arrest in human endometrial epithelial cells.
J. Endocrinol. Invest., 33: 745-750, 2010. (IF:1.654)

29. Shimizu Y, Takeuchi T, Mita S, Mizuguchi K, Kiyono T, Inoue M, Kyo S.
Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression.
Mol. Hum. Reprod., 15: 693-701, 2009. (IF:4.542)

30. Kyo S
#, Mizumoto Y, Takakura M, Hashimoto M, Mori N, Ikoma T, Nakamura M, Inoue M.
Experience and efficacy of a bipolar vessel sealing system for radical abdominal hysterectomy.
Int. J. Gynecol. Cancer, 19: 1658-1661, 2009. (IF:1.941)

31. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimuta T, Oka Y, Tsuboi A, Sugiyama H, Inoue M.
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Anticancer Res., 29: 4779-4784, 2009. (IF:1.713)

32. Kurihara Y, Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, Liu D, Kyo S, Mizuguchi H, Urata Y, Shintani S, Fujiwara T.
Telomerase-specific virotheranostics for human head and neck cancer.
Clin. Cancer Res., 15: 2335-2343, 2009. (IF:7.837)

33. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, Tazawa H,
Kyo S, Mizuguchi H, Urata Y, Tanaka N, Fujiwara T.
A simple biological imaging system for detecting viable human circulating tumor cells.
J. Clin. Invest., 119: 3172-3181, 2009. (IF:12.817)

34. Maida Y, Kyo S
#, Sakaguchi J, Mizumoto Y, Hashimoto M, Mori N, Ikoma T, Nakamura M, Takakura M, Urata Y, Fujiwara T, Inoue M.
Diagnostic potential and limitation of imaging cancer cells in cytological samples using telomerase-specific replicative adenovirus.
Int. J. Oncol., 34: 1549-1556, 2009. (IF:2.657)

35. .Dohi S, Ohno S, Ohno Y, Soma G, Kyo S, Inoue M.
Correlation between WT1 expression and cell proliferation in endometrial cancer. Anticancer Res., 29: 4887-4891, 2009. (IF:1.713)

36. Ikoma T, Kyo S
#, Maida Y, Ozaki S, Takakura M, Nakao S, Inoue M.
Bone marrow-derived cells from male donors can compose endometrial glands in female transplant recipients.
Am. J. Obstet. Gynecol., 201: 608.e1-8, 2009. (IF:3.877)

37. Yoshie M, Miyajima E, Kyo S, Tamura K.
Stathmin, a microtubule regulatory protein, is associated with hypoxia-inducible factor-1α levels in human endometrial and endothelial cells.
Endocrinology, 150: 2413-2418, 2009. (IF:4.717)

38. Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N, Inoue M. Immunohistochemical detection of WT1 protein in endometrial cancer.
Anticancer Res.,29: 1691-1695, 2009. (IF:1.713)

39. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, Jin M, Shimasaki T, Motoo Y, Minamoto T.
Deregulated GSK3β sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.
Clin. Caner Res., 15: 6810-6819, 2009. (IF:7.837)

40. Nakamura M, Bodily JM, Beglin M, Kyo S, Inoue M, Laimins LA.
Hypoxia-specific stabilization of HIF-1α by human papillomaviruses.
Virology, 387; 442-448, 2009. (IF:3.367)

41. Strååt K, Liu C, Rahbar A, Zhu Q, Liu L, Wolmer-Solberg N, Lou F, Liu Z, Shen J, Jia J, Kyo S, Björkholm M, Sjöberg J, Söderberg-Nauclér C, Xu D.
Activation of telomerase by human cytomegalovirus.
J. Natl. Cancer Inst., 101: 488-497, 2009. (IF:14.336)

42. Akutagawa O, Nishi H, Kyo S, Terauchi F, Yamazawa K, Higuma C, Inoue M, Isaka K. Early growth response-1 mediates downregulation of telomerase in cervical cancer.
Cancer Sci., 99:1401-1406, 2008. (IF:3.479)

43. Hashimoto M, Kyo S
#, Hua X, Tahara H, Nakajima M, Takakura M, Sakaguchi J, Maida Y, Nakamura M, Ikoma T, Mizumoto Y, Inoue M.
Role of menin in the regulation of telomerase activity in normal and cancer cells.
Int. J. Oncol., 33: 333-340, 2008. (IF:2.657)

44. Hida N, Nishiyama N, Miyoshi S, Kira S, Segawa K, Uyama T, Mori T, Miyado K, Ikegami Y, Cui C, Kiyono T, Kyo S, Shimizu T, Okano T, Sakamoto M, Ogawa S, Umezawa A.
Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells.
Stem Cells, 26: 1695-1704, 2008. (IF:7.701)

45. Kyo S
#, Hashimoto M, Maida Y, Mizumoto Y, Nakamura M, Takakura M, Inoue M. Analysis of outcome of Stage I-III endometrial cancer treated with systematic operation omitting paraarotic lymphadenectomy.
Eur. J. Gynecol. Oncol., 28: 170-173, 2007. (IF:0.577)

46. Mori N, Kyo S
#, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M.
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosis.
Cancer Sci., 98: 1881-1888, 2007. (IF:3.117)

47. Mizumoto Y, Kyo S
#, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M.
Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Cancer Sci., 98: 652-658, 2007. (IF:3.479)

48. Mizumoto Y, Kyo S
#, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M.
Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Cancer Sci., 98: 652-658, 2007. (IF:3.479)

49. Kato K, Yoshimoto M, Kato K, Adachi S, Yamayoshi A, Arima T, Asanoma K, Kyo S, Nakahata T, Wake N.
Characterization of side-population cells in human normal endometrium.
Hum. Reprod., 22:1214-1223, 2007. (IF:4.670)

50. Cui CH, Uyama T, Miyado K, Terai M, Kyo S, Kiyono T, Umezawa A.
Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation.
Mol. Biol. Cell,18: 1586-1594, 2007. (IF:4.604)

51. Akutagawa O, Nishi H, Kyo S, Higuma C, Inoue M, Isaka K.
Early growth response-1 mediates up-regulation of telomerase in placenta.
Placenta, 28: 920-927, 2007. (IF:3.117)

52. Liu C, Fang X, Ge Z, Jalink M, Kyo S, Björkholm M, Gruber A, Sjöberg J, Xu D.
The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Cancer Res., 67: 2626-2631, 2007. (IF:8.650)

53. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, Nakajima M.
Human CYP2A6 is induced by estrogen via estrogen receptor.
Drug Metab. Dispos., 35: 1935-1941, 2007. (IF:3.361)

54. Komagata S, Nakajima M, Tsuchiya Y, Katoh M, Kizu R, Kyo S, Yokoi T.
Decreased responsiveness of naturally occurring mutants of human estrogen receptor α to estrogens and antiestrogens.
J. Steroid Biochem. Mol. Biol., 100: 79-86, 2006. (IF:3.984)

55. Miyoshi T, Hirohata S, Ogawa H, Doi M, Obika M, Yonezawa T, Sado Y, Kusachi S, Kyo S, Kondo S, Shiratori Y, Hudson BG, Ninomiya Y.
Tumor-specific expression of the RGD-α3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice.
FASEB J., 20: 1904-1906, 2006. (IF:5.704)

56. Toyota H, Kondo S, Kyo S, Mizuguchi J.
Enforced expression of a truncated form of Bax-α (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
Anticancer Res., 26: 99-105, 2006. (IF:1.713)

57. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, Teraishi F, Kyo S, Mizuguchi H, Hashimoto Y, Urata Y, Tanaka N, Fujiwara T.
In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus.
Nat. Med., 12: 1213-1219, 2006. (IF:22.864)

58. Higashi T, Kyo S, Inoue M, Tanii H, Saijoh K.
Novel functional single nucleotide polymorphisms in the latent transforming growth factor-βbinding protein-1L promoter: Effect on latent transforming growth factor-β binding protein-1L expression level and possible prognostic significance in ovarian cancer.
J. Mol. Diagn., 8: 342-350, 2006. (IF:3.952)

59. Maida Y, Kyo S
#, Forsyth NR, Takakura M, Sakaguchi J, Mizumoto Y, Hashimoto M, Nakamura M, Nakao S, Inoue M.
Distinct telomere length regulation in premalignant cervical and endometrial lesions: implications for the roles of telomeres in uterine carcinogenesis.
J. Pathol., 210: 214-223, 2006. (IF:7.585)

60. Kyo S
#, Sakaguchi J, Ohno S, Mizumoto Y, Maida Y, Hashimoto M, Nakamura M, Takakura M, Nakajima M, Masutomi K, Inoue M.
High Twist expression is involved in infiltrative endometrial cancer and affects patient survival.
Hum. Pathol
., 37: 431-438, 2006. (IF:2.843)

61. Mizumoto Y, Kyo S
#, Ohno S, Hashimoto M, Nakamura M, Maida Y, Sakaguchi J, Takakura M, Inoue M, Kiyono T.
Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements.
Oncogene, 25: 5673-5682, 2006. (IF:7.357)

62. Nishimura A, Nakahara T, Ueno T, Sasaki K, Yoshida S, Kyo S, Howley PM, Sakai H. Requirement of E7 oncoprotein for viability of HeLa cells.
Microbes Infect., 8: 984-993, 2006. (IF:2.920)

63. Jagadeesh S, Kyo S, Banerjee PP.
Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells.
Cancer Res
., 66:2107-2115, 2006. (IF:8.650)

64. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, Tanaka M, Inoue M, Yokoi T.
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
J. Clin. Pharmacol., 45: 674-682, 2005. (IF:2.841)

65. Sakaguchi J, Kyo S
#, Kanaya T, Maida Y, Hashimoto M, Nakamura M, Yamada K, Inoue M.
Aberrant expression and mutations of TGF-β receptor type II gene in endometrial cancer.
Gynecol. Oncol
., 98: 427-433, 2005. (IF:3.929)

66. Kanaya T, Kyo S
#, Sakaguchi J, Maida Y, Nakamura M, Takakura M, Hashimoto M, Mizumoto Y, Inoue M.
Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population.
Am. J. Clin. Pathol., 124: 89-96, 2005. (IF:2.881)

67. Alonso MM, Fueyo J, Shay JW. Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C.
Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.
J. Natl. Cancer Inst., 97: 1589-1600, 2005. (IF:14.336)

68. Toh WH, Kyo S, Sabapathy K.
Relief of p53-mediated telomerase suppression by p73.
J. Biol. Chem., 280: 17329-17338, 2005. (IF:4.651)

69.Takakura M, Kyo S
#, Inoue M, Wright WE, Shay JW.
Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells.
Mol. Cell. Biol., 25:8037-8043, 2005. (IF:5.372)

70. Hashimoto M, Kyo S
#, Masutomi K, Maida Y, Sakaguchi J, Mizumoto Y, Nakamura M, Hahn WC, Inoue M.
Analysis of telomeric single-strand overhang length in human endometrial cancers.
FEBS Lett.
, 579: 2959-2964, 2005. (IF:3.582)

71. Ito H, Kanzawa T, Miyoshi T, Hirohata S, Kyo S, Iwamaru A, Aoki H, Kondo Y, Kondo S.
Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.
Hum. Gene Ther., 16: 685-698, 2005. (IF:4.019)

72. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T.
Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’).
Oncogene, 24: 3130-3140, 2005. (IF:7.357)

73. Nakamura M, Masutomi K, Kyo S
#, Hashimoto M, Maida Y, Kanaya T, Tanaka M, Hahn WC, Inoue M.
Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy.
Hum. Gene Ther., 16: 859-868, 2005. (IF:4.019)

74. Takeuchi H, Kanzawa T, Kondo Y, Komata T, Hirohata S, Kyo S, Kondo S.
Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells.
Int. J. Oncol., 25: 57-63, 2004. (IF:2.657)

75. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T.
Telomerase-specific replication-selective virotherapy for human cancer.
Clin. Cancer Res., 10: 285-292. 2004. (IF:7.837)

76. Nakamura M, Kyo S
#, Kanaya T, Yatabe N, Maida Y, Tanaka M, Ishida Y, Fujii C, Kondo T, Inoue M, Mukaida N.
hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin.
Cancer Gene Ther., 11: 1-7, 2004. (IF:2.945)

77. Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T.
Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.
Cancer Res., 64: 6259-6265, 2004(IF:8.650)

78. Yatabe N, Kyo S
#, Maida Y, Nishi H, Nakamura M, Kanaya T, Tanaka M, Isaka K, Ogawa S, Inoue M.
HIF-1-mediated activation of telomerase in cervical cancer cells.
Oncogene, 23: 3708-3715, 2004. (IF:7.357)

79. Terasaki T, Kyo S
#, Takakura M, Maida Y, Tsuchiya H, Tomita K, Inoue M.
Analysis of telomerase activity and telomere length in bone and soft tissue tumors.
Oncol. Rep., 11: 1307-1311, 2004. (IF:2.297)

80. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T.
Human CYP1B1 is regulated by estradiol via estrogen receptor.
Cancer Res
., 64: 3119-3125, 2004. (IF:8.650)

81. Takahashi A, Higashino F, Aoyagi M, Kyo S, Nakata T, Noda M, Shindoh M, Kohgo T, Sano H.
Bisphenol A from dental polycarbonate crown upregulates the expression of hTERT.
J. Biomed. Mater. Res
. B Appl. Biomater., 71: 214-221, 2004. (IF:2.834)

82. Kimura A. Ohmichi M, Kawagoe J, Kyo S, Mabuchi S, Takahashi T, Ohshima C, Arimoto-Ishida E, Nishio Y, Inoue M, Kurachi H, Tasaka K, Murata Y.
Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines.
Oncogene, 23: 4505-4515, 2004. (IF:7.357)

83. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K.
Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT).
Mol. Cell. Biol., 24: 6076-6083, 2004. (IF:5.745)

84. Chen CJ, Kyo S, Liu YC, Cheng YL, Hsieh CB, Chan DC, Yu JC, Harn HJ.
Modulation of human telomerase reverse transcriptase in hepatocellular carcinoma.
World J. Gastroenterol., 10: 638-642, 2004. (IF:2.547)

85. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, Inoue M, Kuroiwa Y,
Yokoi T.
Genetic polymorphisms of CYP2C8 in Japanese population.
Drug Metab. Dispos., 31: 687-690, 2003.(IF:3.361)

86. Tanaka M, Kyo S
#, Kanaya T, Yatabe N, Nakamura M, Maida Y, Okabe M, Inoue M. Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium.
Am. J. Pathol., 163: 295-301, 2003. (IF:4.522)

87. Kanaya T, Kyo S
#, Maida Y, Yatabe N, Tanaka M, Nakamura M. Inoue M.
Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers.
Oncogene, 22: 2352-2360, 2003. (IF:7.357)

88. Kyo S
#, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, Yatabe N, Inoue M. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics.
Am. J. Pathol., 163: 2259-2269, 2003. (IF:4.522)

89. Kyo S
#, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M, Takarada M, Sugawara I, Murakami S, Taira T, Inoue M.
Significance of immunological detection of human telomerase reverse trasncriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase.
Am. J. Pathol., 163: 859-867, 2003. (IF:4.522)

90. Kanzawa T, Komata T, Kyo S, Germano IM, Kondo Y, Kondo S.
Down-regulation of telomerase activity in malignant glioma cells by p27KIP1.
Int. J. Oncol., 23: 1703-1708, 2003. (IF:2.657)

91. Ikeda N, Uemura H, Ishiguro H, Hori M, Hosaka M, Kyo S, Miyamoto K, Takeda E, Kubota Y.
Combination treatment with 1α,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells.
Mol. Cancer Ther., 2:739-746, 2003. (IF:5.599)

92. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S, Ohno T, Taira T, Ariga H, Nakajima K, Hatta M, Kobayashi M, Sano H, Kohgo T, Shindoh M.
EWS/ETS fusions activate telomerase in Ewing’s tumors.
Cancer Res., 63: 8338-8344, 2003. (IF:8.650)

93. Kawagoe J, Ohmichi M, Takahashi T, Ohshima C, Mabuchi S, Takahashi K, Igarashi H, Mori-Abe A, Saitoh M, Du B, Ohta T, Kimura A, Kyo S, Inoue M, Kurachi H. Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line.
J. Biol. Chem., 278:43363-43372, 2003. (IF:4.651)

94. akeda T, Inaba H, Yamazaki M, Kyo S, Miyamoto T, Suzuki S, Ehara T, Kakizawa T, Hara M, DeGroot LJ, Hashizume K.
Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.
J. Clin. Endocrinol. Metab., 88: 3531-3538, 2003. (IF:6.430)

95. Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S, Kondo S.
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Br. J. Cancer, 89: 922-929, 2003. (IF:5.082)

96. Wang Z, Kyo S
#, Maida Y, Takakura M, Tanaka M, Yatabe N, Kanaya T, Nakamura M, Koike K, Hisamoto K, Ohmichi M, Inoue M.
Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
Oncogene, 21: 3517-3524, 2002. (IF:7.357)

97. Yatabe N, Kyo S
#, Kondo S, Kanaya T, Wang Z, Maida Y, Takakura M, Nakamura M, Tanaka M, Inoue M.
2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther.,9: 624-630, 2002. (IF:2.945)

98. Komata T, Kondo Y, Kanzawa T, Ito H, Hirohata S, Koga S, Sumiyoshi H, Takakura M, Inoue M, Barna BP, Germano IM, Kyo S,Kondo S.
Caspace-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells.
Hum. Gene Ther., 13: 1015-1025, 2002. (IF:4.019)

99. Maida Y, Kyo S
#, Kanaya T, Wang Z, Tanaka M, Yatabe N, Nakamura M, Inoue M.
Is the telomerase assay useful for screening of endometrial lesions?
Int. J. Cancer, 100: 714-718, 2002. (IF:6.198)

100. Maida Y, Kyo S
#, Kanaya T, Wang Z, Yatabe N, Tanaka M, Nakamura M, Ohmichi M, Gotoh N, Murakami S, Inoue M.
Direct activation of telomerase by EGF through Ets–mediated transactivation of TERT via MAP kinase signaling pathway.
Oncogene, 21: 4071-4079, 2002. (IF:7.357)

101. Hamada K, Shinomiya H, Asano Y, Kihana T, Iwamoto M, Hanakawa Y, Hashimoto K, Hirose S, Kyo S, Ito M.
Molecular cloning of human squamous cell carcinoma antigen 1 gene and characterization of its promoter.
Biochim. Biophys Acta, 1518: 124-131, 2001. (IF:1.7)

102. Takakura M, Kyo S
#, Sowa Y, Wang Z, Yatabe N, Maida Y, Tanaka M, Inoue M. Telomerase activation by histone deacetylase inhibitor in normal cells.
Nucleic Acids Res., 29: 3006-3011, 2001. (IF:8.278)

103. Crowe DL, Nguyen DC, Tsang KJ, Kyo S.
E2F-1 represses transcription of the human telomerase reverse transcriptase gene.
Nucleic Acids Res., 29: 2789-2794, 2001. (IF:8.278)

104. Yang H, Kyo S, Takakura M, Sun L.
Autocrine transforming growth factor β suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells.
Cell Growth Differ., 12: 119-127, 2001. (IF:4.353)

105. Oh ST, Kyo S, Laimins LA.
Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites.
J. Virol., 75: 5559-5566, 2001. (IF: 5.076)

106. Komata T, Koga S, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S, Kondo Y.
A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter.
Int. J. Oncol., 19, 1015-1020, 2001. (IF:2.657)

107. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW,
Kyo S, Kondo S.
Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.
Cancer Res., 61: 5796-5802, 2001. (IF:8.650)

108. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo.
Anticancer Res., 21: 1937-1943, 2001. (IF:1.713)

109. Wang Z, Kyo S
#, Takakura M, Tanaka M, Yatabe N, Maida Y, Fujiwara M, Hayakawa J, Ohmichi M, Koike K, Inoue M.
Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway.
Cancer Res., 60: 5376-5381, 2000. (IF:8.650)

110. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S.
A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter.
Hum. Gene Ther., 11: 1397-1406, 2000. (IF:4.019)

111. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B.
Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
Cancer Res., 60: 5359-5364, 2000. (IF:8.650)

112. Fujimoto K, Kyo S
#, Takakura M, Kanaya T, Kitagawa Y, Itoh H, Takahashi M, Inoue M.
Identification and characterization of negative regulatory elements of human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT.
Nucleic Acids Res., 28: 2557-2562, 2000. (IF:8.278)

113. Kanaya T, Kyo S
#, Hamada K, Takakura M, Kitagawa Y, Harada H, Inoue M.
Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription.
Clin. Cancer Res., 6: 1239-1247, 2000.(IF:7.837)

114 Kitagawa Y, Kyo S
#, Takakura M, Kanaya T, Koshida K, Namiki M, Inoue M. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT.
Clin. Cancer Res., 6: 2868-2875, 2000.(IF:7.837)

115. Kyo S
#, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M.
Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).
Nucleic Acids Res., 28: 669-677, 2000. (IF:8.278)

116. Kyo S
#, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M. Estrogen activates telomerase.
Cancer Res., 59: 5917-5921, 1999. (IF:8.650)

117. Kyo S
#, Kanaya T, Takakura M, Tanaka M, Yamashita A, Inoue H, Inoue M.
Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors.
Int. J. Cancer, 80: 804-809, 1999. (IF:6.198)

118. Kyo S
#, Kanaya T, Takakura M, Tanaka M, Inoue M.
Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues.
Int. J. Cancer, 80: 60-63, 1999. (IF:6.198)

119. Takakura M, Kyo S
#, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M.
Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells.
Cancer Res., 59: 551-557, 1999. (IF:8.650)

120. Inoue T, Oka K, Yong-Il H, Vousden KH, Kyo S, Jing P, Hakura A, Yutsudo M. Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6.
Mol. Carcinog., 21: 215-222, 1998. (IF:4.269)

121. Ito H, Kyo S
#, Kanaya T, Takakura M, Koshida K, Namiki M, Inoue M.
Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer.
Clin. Cancer Res., 4: 2807-2810, 1998. (IF:7.837)

122. Ito H, Kyo S
#, Kanaya T, Takakura M, Inoue M, Namiki M.
Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer.
Clin. Cancer Res., 4: 1603-1608, 1998.(IF:7.837)

123. Kanaya T, Kyo S
#, Takakura M, Ito H, Namiki M, Inoue M.
hTERT is a critical determinant of telomerase activity in renal-cell carcinoma.
Int. J. Cancer, 78: 539-543, 1998. (IF:6.198)

124. Takakura M, Kyo S
#, Kanaya T, Tanaka M, Inoue M.
Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer.
Cancer Res., 58: 1558-1561, 1998. (IF:8.650)

125. Kyo S
#, Takakura M, Tanaka M, Kanaya T, Inoue M.
Telomerase activity in cervical cancer is quantitatively distinct from that in its precursor lesions.
Int. J. Cancer, 79: 66-70, 1998. (IF:6.198)

126. Kyo S
#, Takakura M, Tanaka M, Murakami K, Saitoh R, Hirano H, Inoue M. Quantitative differences in telomerase activity among malignant, premalignant, and benign ovarian lesions.
Clin. Cancer Res., 4: 399-405, 1998. (IF:7.837)

127. Tanaka M, Kyo S
#, Takakura M, Kanaya T, Sagawa T, Yamashita K, Okada Y, Hiyama E, Inoue M.
Expression of telomerase activity in human endometrium is localized to epithelial glandular cells and regulated in a menstrual phase-dependent manner correlated with cell proliferation.
Am. J. Pathol., 153: 1985-1991, 1998. (IF:4.522)

128. Kyo S
#, Takakura M, Ishikawa H, Sasagawa T, Satake S, Tateno M, Inoue M. Application of telomerase assay for the screening of cervical lesions.
Cancer Res., 57: 1863-1867, 1997. (IF:8.650)

129. Kyo S
#, Kunimi K, Uchibayashi T, Namiki M, Inoue M.
Telomerase activity in human urothelial tumors.
Am. J. Clin. Pathol., 107: 555-560, 1997. (IF:2.881)

130. Kyo S
#, Takakura M, Kohama T, Inoue M.
Telomerase activity in human endometrium.
Cancer Res., 57: 610-614, 1997. (IF:8.650)

131. Kyo S
#, Takakura M, Tanaka M, Kanaya T, Sagawa T, Kohama T, Ishikawa H, Nakano T, Shimoya K, Inoue M.
Expression of telomerase activity in human chorion.
Biochem. Biophys. Res. Commun., 241: 498-503, 1997. (IF:2.406)

132. Kyo S, Klumpp DJ, Inoue M, Kanaya T, Laimins LA.
Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells.
J. Gen. Virol., 78: 401-411, 1997. (IF:3.127)

133. Kanaya T, Kyo S
#, Laimins LA.
The 5' region of the human papillomavirus type 31 upstream regulatory region acts as an enhancer which augments viral early expression through the action of YY1.
Virology, 237: 159-169, 1997. (IF:3.367)

134. Kyo S
#, Kanaya T, Ishikawa H, Ueno H, Inoue M.
Telomerase activity in gynecological tumors.
Clin. Cancer Res., 2: 2023-2028, 1996. (IF:7.837)

135. Fujita M, Shroyer KR, Markham NE, Inoue M, Iwamoto S, Kyo S, Enomoto T. Association of human papillomavirus with malignant and premalignant lesions of the uterine endometrium.
Hum. Pathol., 26: 650-658, 1995. (IF:2.843)

136. Kyo S, Tam A, Laimins LA.
Transcriptional activity of human papillomavirus type 31b enhancer is regulated through synergistic interaction of AP1 with two novel cellular factors.
Virology, 211: 184-197, 1995. (IF:3.367)

137. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G.
Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors.
Cancer Res., 54: 3049-3053, 1994. (IF:8.650)

138. Inoue T, Kyo S, Kiyono T, Ishibashi M, Ishiwatari H, Hwang YI, Yutsudo M, Hakura A. Correlation between tumorigenicity and expression levels or splicing patterns of transcripts of the human papillomavirus type 16 E6 gene.
Jpn. J. Cancer Res., 85: 357-363, 1994. (IF:3.479)

139. Kyo S
#, Inoue M, Hayasaka N, Inoue T, Yutsudo M, Tanizawa O, Hakura A.
Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines.
Virology, 200: 130-139, 1994. (IF:3.367)

140. Kyo S
#, Inoue M, Koyama M, Fujita M, Tanizawa O, Hakura A.
Detection of high-risk human papillomavirus in the cervix and semen of sex partners.
J. Infect. Dis., 170: 682-685, 1994. (IF: 5.848)

141. Kyo S
#, Inoue M, Nishio Y, Nakanishi K., Akira S, Inoue H, Yutsudo M, Tanizawa O, Hakura A.
NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region.
J. Virol.,67: 1058-1066, 1993. (学位論文)(IF: 5.076)

欧文症例報告

142. Kyo S
#, Takakura M, Nishida S, Ozaki S, Oda M, Inoue M.
Massive hemothorax due to diaphragmatic endometriosis after a laparoscopic cystectomy of an ovarian endometrioma in a patient without a history of thoracic endometriosis.
Arch. Gynecol. Obstet., 286: 411-414, 2012. (IF:1.330)

143. Tanaka M, Kyo S, Inoue M, Kojima T.
Conservative management and vaginal delivery following ruptured renal angiomyolipoma.
Obstet. Gynecol., 98: 932-933, 2001. (IF:4.798)

144. Kyo S
#, Kanaya T, Takakura M, Inoue M.
A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and Il-6.
Gynecol. Oncol., 78: 383-387, 2000. (IF:3.929)

145. Maida Y, Kyo S
#, Takakura M, Kanaya T, Inoue M.
Ovarian endometrioid adenocarcinoma with ectopic production of α-fetoprotein. Gynecol. Oncol., 71: 133-136, 1998. (IF:3.929)



欧文総説

146. Kyo S
#.Endometrial cancer stem cells: Are they a possible therapeutic target?
Curr. Obstet. Gynecol. Rep.,2:1-10, 2013.(IF: not determined)

147. Kyo S
#, Maida Y, Inoue M.
Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions.
Cancer Lett., 308: 123-133, 2011.(IF:4.258)

148. Kyo S
#, Takakura M, Fujiwara T, Inoue M.
Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.
Cancer Sci., 99: 1528-1538, 2008.(IF:3.479)

149. Kyo S
# and Inoue M.
How to inhibit telomerase activity for cancer therapy.
Curr. Med. Chem.
Anticancer Agents, 2: 613-626, 2002. (IF:4.07)

150. Kyo S
# and Inoue M.
Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy?
Oncogene, 21: 688-697, 2002.(IF:7.357)

151. Kyo S
#, Takakura M, Inoue M.
Telomerase activity in cancer as a diagnostic and therapeutic target.
Histol. Histopathol., 15, 813-824, 2000. (IF:2.281)

(IF: 781.9) (~2014)
(Citatation index: 6869) (~2014)